Jupiter Wellness (NASDAQ: JUPW), a leading developer of cannabidiol (“CBD”)-based medical therapeutics and wellness products, has initiated a clinical study evaluating the treatment of herpes labialis (cold sores) for its prescription topical cream candidate JW-100. The company believes this trial may be the first to analyze the efficacy of a combination CBD-aspartame product in the treatment of herpes labialis. JUPW’s topical cream, JW-100, features a dual mechanism of action and relief combined with CBD’s potential ability to induce apoptosis in epithelial cells infected with Kaposi sarcoma-associated herpes virus, with aspartame’s analgesic and anti-inflammatory properties. The study will include 40 patients enrolled through clinical sites in both Europe and Asia. Patients will have been diagnosed with recurrent herpes labialis infection (“HSV”) with initial infection at least a year previously. “We are rapidly advancing our clinical pipeline with our third indication,” said Jupiter CEO Brian John. “Herpes cold sores are common, with an estimated 48% of Americans aged 14-49 having had the HSV-1 virus. We believe JW-100 has the potential to treat and provide relief with fewer side effects than the treatments on the market today. This exploratory clinical trial is in line with a Phase I FDA study, and therefore we believe the resulting data will be a valuable addition to the Investigational New Drug (‘IND’) application we plan to file with the FDA for advanced stage trials in the U.S.”
To view the full press release, visit https://nnw.fm/b3B20
About Jupiter Wellness Inc.
Jupiter Wellness is a leading developer of cannabidiol (“CBD”)-based medical therapeutics and wellness products. The company’s clinical pipeline of prescription CBD-enhanced, skin-care therapeutics address indications including eczema, burns, herpes cold sores and skin cancer. Jupiter generates revenues from a growing line of proprietary over-the-counter skin-care products including its flagship CaniSun(TM) sunscreen and other wellness brands sold through its robust distribution platform. For additional information about this company, please visit www.JupiterWellnessInc.com.
NOTE TO INVESTORS: The latest news and updates relating to JUPW are available in the company’s newsroom at https://nnw.fm/JUPW
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork
